[The pharmacokinetic aspects of the clinical action of gidazepam].
The nature of a relation between the efficiency of gidazepam and the concentrations of its desalkyl metabolite in the plasma of 18 patients after single use and course therapy of the drug during 21 days was studied. There was a significant relationship between the plasma levels of the desalkyl metabolite of gidazepam following 4 hours and the anti-anxious effect of gidazepam 4 and 24 hours after its single dose. There was a correlation between the steady-state plasma concentrations of desalkylgidazepam on day 14 of course therapy and the tranquilizing effect of the drug.
Zherdev
V P
VP
Neznamov
G G
GG
Kolyvanov
G B
GB
Litvin
A A
AA
Otabekova
S G
SG
D000328:Adult; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D001569:Benzodiazepines; D001570:Benzodiazepinones / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid / Q000295:instrumentation / Q000379:methods; D003640:Dealkylation; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008875:Middle Aged; D009497:Neurotic Disorders / Q000097:blood / Q000188:drug therapy; D013997:Time Factors
D014151:Anti-Anxiety Agents; D001570:Benzodiazepinones; D001569:Benzodiazepines; C077010:gidazepam
Farmakokineticheskie aspekty klinicheskogo deĭstviia gidazepama.